Abstract
Low-dose radiotherapy (LD-RT) has historically been used to treat severe bacterial and viral pneumonia due to its immunomodulatory properties. However, this technique has been delayed since the advent of antibiotics and the carcinogenic risk associated with radiation therapy. Currently, it represents an alternative therapeutic in the SARS-CoV-2 pandemic which leads sometimes to fatal pneumonia, especially given the limited availability of effective treatments for severe forms of pneumonia. Numerous in vitro and in vivo studies have demonstrated the anti-inflammatory effect of LD-RT and have reported clinical and biological improvement in patients with severe pneumonia. In this literature review, we report the data and results of various published clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.